A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-Week virologic results of ACTG A5086

Journal of Infectious Diseases

Volumn 194, Issue 9, 2006, Pages 1309-1318

  Benson, Constance A ^a,i   Vaida, Florin ^a   Havlir, Diane V ^b   Downey, Gerald F ^c   Lederman, Michael M ^d   Gulick, Roy M ^e   Glesby, Marshall J ^e   Wantman, Michael ^c   Bixby, Christian J ^f   Rinehart, Alex R ^g   Snyder, Sally ^h   Wang, Rui ^c   Patel, Sheran ^f   Mellors, John W ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g VircoLab Inc   (United States)

^h SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VIRUS GENOME; VIRUS LOAD; VIRUS MUTATION; WILD TYPE;

ADULT; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHYLOGENY; TIME FACTORS;

EID: 33750317852     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/508289     Document Type: Article

References (30)

1. Falloon J, Ait-Khaled M, Thomas DA, et al. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS 2002; 16:387-96.
2. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 1999; 13:F17-21.
3. Walmsley SL, Becker MI, Zhang M, Humar A, Harrigan PR. Predictors of virological response in HIV-infected patients to salvage antiretroviral therapy that includes nelfinavir. Antivir Ther 2001; 6:47-54.
4. Tebas P, Patick AK, Kane EM, et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS 1999; 13:F23-8.
5. Hammer SM, Bassett R, Squires KE, et al. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther 2003; 8:507-18.
6. Deeks SG, Grant RM, Beatty GW, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998; 12:F97-102.
7. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181:946-53.
8. Miller V, Gute P, Carlebach A, et al. Baseline resistance and virological response to mega-HAART salvage therapies [abstract 130]. In: Program and abstracts of the 6th Conference on Retro viruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999:92.
9. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis 2000; 182:1375-84.
10. Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002; 288:169-80.
11. Montaner JS, Harrigan PR, Jahnke N, et al. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 2001; 15:61-9.
12. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14:2857-67.
13. Youle M, Tyrer M, Fisher M, et al. Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen. J Acquir Immune Defic Syndr 2002; 29:58-61.
14. Miller V, Cozzi-Lepri A, Hertogs K, et al. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antivir Ther 2000; 5:49-55.
15. Miller V, Rottmann C, Hertogs K. Mega-HAART, resistance, and drug holidays. 2nd International Workshop on Salvage Therapy for HIV Infection. Antivir Ther 1999;4(Suppl 1):27-8.
16. Miller V, Sabin C, Hertogs K, et al. Antiretroviral treatment interruptions in patients with treatment failure: analyses from the Frankfurt HIV cohort. 3rd International Workshop on Salvage Therapy for HIV Infection. Antivir Ther 2000; 5(Suppl 2):22.
17. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-80.
18. Deeks SG, Grant RM, Wrin T, et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 2003; 17:361-70.
19. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837-46.
20. Ruiz L, Ribera E, Bonjoch A, et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. J Infect Dis 2003; 188:977-85.
21. Lawrence J, Hulsiek KH, Thackeray L, et al. Final results of CPCRA 064: a randomized trial examining structured treatment interruption for patients failing therapy with multi-drug resistant HIV [abstract 579]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005:264.
22. Walmsley S, LaPierre N, Loutfy M, et al. CTN 164: a prospective randomized trial of structured treatment interruption vs immediate switching in HIV-infected patients experiencing virologic failure on HAART [abstract 580]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005: 265.
23. Beatty G, Lu J, Hunt P, et al. Randomized pilot study of immediate enfuvirtide-based therapy vs a treatment interruption followed by enfuvirtide-based therapy in highly treatment-experienced patients [abstract 581]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005:265.
24. Katlama C, Dominguez S, Gourlain K, et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 2004; 18:217-26.
25. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med 2005; 13:51-7.
26. Palmer S, Kearney M, Maldarelli F, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005; 43:406-13.
27. Felsenstein J. PHYLIP-phylogeny inference package (version 3.2). Cladistics 1989; 5:164-6.
28. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-8.
29. Hance AJ, Lemiale V, Izopet J, et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 2001; 75:6410-7.
30. Ghosn J, Wirden M, Ktorza N, et al. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS 2005; 19:1643-7.